Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Status:
Terminated
Trial end date:
2017-03-07
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if giving genetically changed immune
cells, called T-cells, after chemotherapy will improve the response to a stem cell
transplant. The safety of this treatment will also be studied.
The process of changing the DNA (the genetic material in cells) of these T-cells is called
"gene transfer." Researchers want to learn if these genetically-changed T-cells are effective
in attacking cancer cells in patients with leukemia, MDS, lymphoma, Hodgkin disease, or MM,
after they have received an allogeneic stem cell transplant.
The chemotherapy you will be given on study is fludarabine, melphalan, and alemtuzumab. These
drugs are designed to stop the growth of cancer cells, which may cause the cancer cells to
die. This chemotherapy is also designed to block your body's ability to reject the donor's
stem cells.
Researchers also want to learn if giving AP1903 will help the symptoms of graft-versus-host
disease (GvHD) that may occur after the T-cell infusion. GvHD occurs when donor cells attack
the cells of the person receiving the stem cell transplant.